inositol has been researched along with Bipolar Disorder in 94 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the relationship between brain lithium levels and the metabolites N-acetyl aspartate (NAA) and myo-inositol (myo-Ino) in the anterior cingulate cortex of a group of older adults with bipolar disorder (BD)." | 9.13 | Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. ( Berlow, YA; Finn, CT; Forester, BP; Moore, CM; Renshaw, PF; Wardrop, M, 2008) |
| " We used different keywords, including bipolar disorder, lithium and valproic acid, inositol role in bipolar disorder, side effects, inositol depletion, supplementation of inositols under lithium treatment, inositol role in metabolism, hypothyroidism, renal and cardiac functionality." | 9.12 | Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid. ( D'Ambrosio, F; Di Lorenzo, C; Janiri, L, 2021) |
| "The inositol supplements had a significantly beneficial effect on the psoriasis of patients taking lithium." | 9.11 | The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. ( Allan, SJ; Herd, RM; Kavanagh, GM; Savin, JA, 2004) |
| "This project was designed to compare differences in brain proton spectra between children and adolescents with bipolar disorder (BPD) and gender and age-matched normal controls, and to measure changes in myo-inositol levels following lithium therapy, utilizing in vivo proton magnetic resonance spectroscopy (1H MRS)." | 9.09 | Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. ( Belin, T; Davanzo, P; McCracken, J; Oshiro, T; Strober, M; Thomas, MA; Yue, K, 2001) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 8.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "The preclinical and clinical MRS findings were generally supportive of the involvement of myo-inositol in bipolar disorder and its treatment." | 8.82 | Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects." | 7.79 | A safe lithium mimetic for bipolar disorder. ( Aley, PK; Antoniadou, I; Baldwin, R; Churchill, GC; Halliday, AC; Kuznetsova, OV; Sharp, T; Singh, N; Thomas, JM; Vasudevan, SR; Woon, EC, 2013) |
| "Serial assessments of anterior cingulate cortex choline and myo-inositol metabolism were performed in nine subjects with bipolar disorder, taking either lithium or valproate, and 14 controls." | 7.70 | Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. ( Babb, SM; Breeze, JL; Cohen, BM; Frederick, BB; Gruber, SA; Hennen, J; Moore, CM; Renshaw, PF; Stoll, AL; Villafuerte, RA; Yurgelun-Todd, DA, 2000) |
| "Inositol uptake was measured at concentrations of 25, 40 and 50 microM in human astrocytoma cell cultures treated for 1-3 weeks with pharmacologically relevant concentrations of LiCl, valproic acid or carbamazepine as well as in control cultures that had not been treated with any drug." | 7.70 | Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. ( Belmaker, RH; Bersudsky, Y; Hertz, L; Simkin, M; Wolfson, M; Zinger, E, 2000) |
| "The frontal cortex inositol levels of the suicide victims and the patients with bipolar disorder were significantly less than those of the normal comparison group." | 7.69 | Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. ( Agam, G; Belmaker, RH; Hyde, TM; Kleinman, JE; Shimon, H, 1997) |
| "Thus, the Li-pilocarpine seizure model may, despite its lack of face validity, be a biochemical marker for a model of mania treatment in animals." | 6.44 | Lithium-pilocarpine seizures as a model for lithium action in mania. ( Belmaker, RH; Bersudsky, Y, 2007) |
| "Pilocarpine was administered after 1 week of treatment, and behavior including seizures was assessed using rating scale." | 5.42 | Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder. ( Agam, G; Belmaker, RH; Bersudsky, Y; Shtein, L, 2015) |
| "We investigated the relationship between brain lithium levels and the metabolites N-acetyl aspartate (NAA) and myo-inositol (myo-Ino) in the anterior cingulate cortex of a group of older adults with bipolar disorder (BD)." | 5.13 | Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. ( Berlow, YA; Finn, CT; Forester, BP; Moore, CM; Renshaw, PF; Wardrop, M, 2008) |
| " We used different keywords, including bipolar disorder, lithium and valproic acid, inositol role in bipolar disorder, side effects, inositol depletion, supplementation of inositols under lithium treatment, inositol role in metabolism, hypothyroidism, renal and cardiac functionality." | 5.12 | Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid. ( D'Ambrosio, F; Di Lorenzo, C; Janiri, L, 2021) |
| "The inositol supplements had a significantly beneficial effect on the psoriasis of patients taking lithium." | 5.11 | The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. ( Allan, SJ; Herd, RM; Kavanagh, GM; Savin, JA, 2004) |
| "This project was designed to compare differences in brain proton spectra between children and adolescents with bipolar disorder (BPD) and gender and age-matched normal controls, and to measure changes in myo-inositol levels following lithium therapy, utilizing in vivo proton magnetic resonance spectroscopy (1H MRS)." | 5.09 | Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. ( Belin, T; Davanzo, P; McCracken, J; Oshiro, T; Strober, M; Thomas, MA; Yue, K, 2001) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 4.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "We conducted a Medline search for clinical trials conducted with humans, published in English from 1960 to 2012 using nutritional supplements such as n-3, chromium, inositol, choline, magnesium, folate and tryptophan alone or in combination with pharmacotherapies for the treatment of bipolar disorder." | 4.89 | Nutrient-based therapies for bipolar disorder: a systematic review. ( Deckersbach, T; Nierenberg, AA; Peters, AT; Sylvia, LG, 2013) |
| " Omega-3 fatty acids and lecithin/ choline have preliminary data indicating potential utility in the CAM treatment for bipolar disorder while S-adenosyl methionine (SAM-e) and inositol have some data supporting their efficacy in the treatment of depressive symptoms." | 4.84 | Complementary medicines in pediatric bipolar disorder. ( Bishop, JR; Bogarapu, S; Krueger, CD; Pavuluri, MN, 2008) |
| "The preclinical and clinical MRS findings were generally supportive of the involvement of myo-inositol in bipolar disorder and its treatment." | 4.82 | Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "We assessed and correlated neurochemical levels and cognitive functions in left dorsolateral prefrontal cortex (DLPFC) and left hippocampus in euthymic patients with bipolar disorder and compared these with healthy controls METHODOLOGY: Twenty-five right-handed euthymic patients (HAM-D score < 7, and YMRS score < 7) with bipolar disorder and 20 age and gender matched controls were compared for neurometabolites (n-acetylaspartate - tNAA, choline - Cho, creatinine - Cr, myoinositol - Ins, and glutamine/glutamate - Glu/Gln) measured in left DLPFC and left hippocampus using single voxel magnetic resonance spectroscopy (MRS) and cognitive functions assessed using trail making test (TMT - A and B), wisconsin card sorting test (WCST), and wechsler memory scale (WMS-III Indian adaptation)." | 4.12 | Neurochemical correlates of cognitive functions in euthymic patients with bipolar disorder: ( Bhargava, R; Chadda, RK; Gupta, R; Jagannathan, NR; Sharma, U; Sood, M, 2022) |
| " The enzymatic activity of IMPase is inhibited by lithium, a drug used for the treatment of mood swings seen in bipolar disorder." | 3.80 | Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis. ( Gondo, Y; Hida, A; Iwayama, Y; Mishima, K; Murata, T; Ohba, H; Ohnishi, T; Watanabe, A; Yoshikawa, T, 2014) |
| "We wished to determine whether decreases in N-acetyl aspartate (NAA) and increases in myoinositol (mI) concentrations as a ratio of creatine (Cr) occurred in the dorsolateral prefrontal cortex (DLPFC) of pediatric offspring of parents with bipolar disorder (BD) and a healthy comparison group (HC) over a 5-year period using proton magnetic resonance spectroscopy ((1)H-MRS)." | 3.79 | Prospective neurochemical characterization of child offspring of parents with bipolar disorder. ( Adleman, NE; Bararpour, L; Chang, KD; Howe, M; Jo, B; Kelley, RG; Singh, MK; Spielman, D, 2013) |
| "Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects." | 3.79 | A safe lithium mimetic for bipolar disorder. ( Aley, PK; Antoniadou, I; Baldwin, R; Churchill, GC; Halliday, AC; Kuznetsova, OV; Sharp, T; Singh, N; Thomas, JM; Vasudevan, SR; Woon, EC, 2013) |
| "We aimed to compare concentrations of N-acetyl aspartate, myo-inositol, and other neurometabolites in the cerebellar vermis of offspring at risk for bipolar disorder (BD) and healthy controls to examine whether changes in these neuronal metabolite concentrations occur in at-risk offspring prior to the onset of mania." | 3.77 | Neurochemical deficits in the cerebellar vermis in child offspring of parents with bipolar disorder. ( Acquaye, T; Adams, E; Chang, KD; Howe, M; Kelley, R; Libby, A; Reiss, A; Singh, MK; Spielman, D, 2011) |
| "The few studies applying single-voxel ¹H spectroscopy in children and adolescents with bipolar disorder (BD) have reported low N-acetyl-aspartate (NAA) levels in the dorsolateral prefrontal cortex (DLPFC), and high myo-inositol / phosphocreatine plus creatine (PCr+Cr) ratios in the anterior cingulate." | 3.77 | Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study. ( Caetano, SC; Chen, HH; Fonseca, M; Hatch, JP; Hunter, K; Lafer, B; Nicoletti, M; Olvera, RL; Pliszka, SR; Sanches, M; Soares, JC; Stanley, JA, 2011) |
| "Lithium inhibits inositol monophosphatase at therapeutically effective concentrations, and it has been hypothesized that depletion of brain inositol levels is an important chemical alteration for lithium's therapeutic efficacy in bipolar disorder." | 3.73 | Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. ( Brandish, PE; Duenwald, SJ; Forbes, JE; Hodor, P; Holder, DJ; Kleinhanz, RR; Liu, Y; McWhorter, ME; Na, S; Parrish, ML; Phillips, RL; Renger, JJ; Sankaranarayanan, S; Scolnick, EM; Simon, AJ; Su, M; Szumiloski, J, 2005) |
| "Children with ADHD had a significantly higher ratio of glutamate plus glutamine to myo-inositol-containing compounds than children with ADHD plus bipolar disorder and healthy children." | 3.73 | Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Mick, E; Moore, CM; Randall, E; Renshaw, PF; Wardrop, M; Wozniak, J, 2006) |
| "Two leading hypotheses to explain lithium action in bipolar disorder propose either inositol depletion or inhibition of GSK-3 as mechanisms of action." | 3.73 | SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. ( Agam, G; Belmaker, RH; Berry, GT; Bersudsky, Y; Buccafusca, R; Johanson, RA; Klein, PS; O'Brien, WT; Shaldubina, A, 2006) |
| "The patients with bipolar disorder showed significantly higher anterior cingulate myo-inositol/creatine-phosphocreatine and myo-inositol (mmol/liter) levels than the patients with intermittent explosive disorder and the normal comparison subjects." | 3.72 | Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. ( Barnett, S; Belin, T; Davanzo, P; McCracken, J; Mintz, J; Santoro, E; Thomas, MA; Venkatraman, TN; Yue, K, 2003) |
| "Inositol uptake was measured at concentrations of 25, 40 and 50 microM in human astrocytoma cell cultures treated for 1-3 weeks with pharmacologically relevant concentrations of LiCl, valproic acid or carbamazepine as well as in control cultures that had not been treated with any drug." | 3.70 | Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. ( Belmaker, RH; Bersudsky, Y; Hertz, L; Simkin, M; Wolfson, M; Zinger, E, 2000) |
| "Serial assessments of anterior cingulate cortex choline and myo-inositol metabolism were performed in nine subjects with bipolar disorder, taking either lithium or valproate, and 14 controls." | 3.70 | Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. ( Babb, SM; Breeze, JL; Cohen, BM; Frederick, BB; Gruber, SA; Hennen, J; Moore, CM; Renshaw, PF; Stoll, AL; Villafuerte, RA; Yurgelun-Todd, DA, 2000) |
| " The anticonvulsant drugs valproate and carbamazepine are emerging as efficacious alternative and adjunctive treatments for bipolar disorder." | 3.69 | Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? ( Lenox, RH; McNamara, RK; Watson, DG; Watterson, JM, 1996) |
| "The frontal cortex inositol levels of the suicide victims and the patients with bipolar disorder were significantly less than those of the normal comparison group." | 3.69 | Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. ( Agam, G; Belmaker, RH; Hyde, TM; Kleinman, JE; Shimon, H, 1997) |
| "omega-3 FAs group only), and CGI-I Mania, CGI-I MDD, and CGI-I Anxiety scores <2." | 3.11 | A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5-12. ( Biederman, J; Ceranoglu, A; Cook, E; DiSalvo, M; Faraone, SV; Farrell, A; Joshi, G; Uchida, M; Vaudreuil, C; Wozniak, J, 2022) |
| "Twenty-six adolescents with bipolar depression participated in an 8-week placebo-controlled trial of QUET monotherapy." | 2.77 | Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression. ( Adler, C; Bryan, H; Chang, K; Chu, WJ; Delbello, M; Eliassen, J; Garrett, A; Howe, M; Kelley, R; Mills, N; Spielman, D; Strakowski, SM, 2012) |
| "Despite promising new therapies, bipolar depression remains difficult to treat." | 2.72 | Inositol augmentation of lithium or valproate for bipolar depression. ( Culhane, M; Demopulos, C; Eden Evins, A; Grandin, LD; Nierenberg, AA; Ogutha, J; Sachs, GS; Yovel, I, 2006) |
| " However, the study suggests that chronic administration of sodium valproate to patients does not lead to similar changes in NAA concentrations." | 2.71 | Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. ( Asghar, SJ; Hanstock, CC; O'Donnell, T; Silverstone, PH; Ulrich, M; Wu, RH, 2003) |
| "Inositol is a constituent of the intracellular phosphatidyl inositol (PI) second messenger system, which is linked to various neurotransmitter receptors." | 2.69 | Inositol as an add-on treatment for bipolar depression. ( Buttenfield, J; Chengappa, KN; Gershon, S; Hardan, A; Kupfer, DJ; Levine, J; Luther, J; Mallinger, AG; Pollock, B; Vagnucci, A; Verfaille, S, 2000) |
| "Thus, the Li-pilocarpine seizure model may, despite its lack of face validity, be a biochemical marker for a model of mania treatment in animals." | 2.44 | Lithium-pilocarpine seizures as a model for lithium action in mania. ( Belmaker, RH; Bersudsky, Y, 2007) |
| "Myo-inositol is an important part of the phosphatidylinositol second messenger system (PI-cycle)." | 2.43 | A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "Pilocarpine was administered after 1 week of treatment, and behavior including seizures was assessed using rating scale." | 1.42 | Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder. ( Agam, G; Belmaker, RH; Bersudsky, Y; Shtein, L, 2015) |
| "Inositol content was studied gas chromatographically and inositol uptake by following 3H-inositol incorporation at various concentrations." | 1.31 | Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. ( Agam, G; Belmaker, RH; Ebstein, RP; Nemanov, L; Shapiro, J; Vainer, E, 2002) |
| "CSF inositol was reported to be reduced in depression and inositol has been reported to be effective in treatment of depression." | 1.29 | CSF inositol does not predict antidepressant response to inositol. Short communication. ( Agam, G; Belmaker, RH; Bersudsky, Y; Kurtzman, L; Levine, J; Rapoport, A; Shapiro, J; Zimmerman, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.06) | 18.7374 |
| 1990's | 16 (17.02) | 18.2507 |
| 2000's | 51 (54.26) | 29.6817 |
| 2010's | 21 (22.34) | 24.3611 |
| 2020's | 5 (5.32) | 2.80 |
| Authors | Studies |
|---|---|
| Fauroux, CM | 1 |
| Lee, M | 1 |
| Cullis, PM | 1 |
| Douglas, KT | 1 |
| Gore, MG | 1 |
| Freeman, S | 1 |
| Janiri, L | 1 |
| D'Ambrosio, F | 1 |
| Di Lorenzo, C | 1 |
| Gupta, R | 1 |
| Sood, M | 1 |
| Sharma, U | 1 |
| Bhargava, R | 1 |
| Jagannathan, NR | 1 |
| Chadda, RK | 1 |
| Wozniak, J | 4 |
| Farrell, A | 1 |
| DiSalvo, M | 1 |
| Ceranoglu, A | 1 |
| Uchida, M | 1 |
| Vaudreuil, C | 1 |
| Joshi, G | 1 |
| Faraone, SV | 2 |
| Cook, E | 1 |
| Biederman, J | 3 |
| Soeiro-de-Souza, MG | 3 |
| Scotti-Muzzi, E | 1 |
| Fernandes, F | 1 |
| De Sousa, RT | 2 |
| Leite, CC | 2 |
| Otaduy, MC | 2 |
| Machado-Vieira, R | 5 |
| Recart, VM | 1 |
| Spohr, L | 1 |
| Soares, MSP | 1 |
| Luduvico, KP | 1 |
| Stefanello, FM | 1 |
| Spanevello, RM | 1 |
| Bond, DJ | 1 |
| Silveira, LE | 1 |
| MacMillan, EL | 1 |
| Torres, IJ | 1 |
| Lang, DJ | 1 |
| Su, W | 1 |
| Honer, WG | 1 |
| Lam, RW | 1 |
| Yatham, LN | 2 |
| Szulc, A | 1 |
| Wiedlocha, M | 1 |
| Waszkiewicz, N | 1 |
| Galińska-Skok, B | 1 |
| Marcinowicz, P | 1 |
| Gierus, J | 1 |
| Mosiolek, A | 1 |
| Otaduy, MCG | 1 |
| Moreno, RA | 1 |
| Nery, FG | 1 |
| Leite, C | 1 |
| Lafer, B | 3 |
| Saiardi, A | 1 |
| Mudge, AW | 1 |
| Gigante, AD | 1 |
| Singh, MK | 2 |
| Jo, B | 1 |
| Adleman, NE | 1 |
| Howe, M | 3 |
| Bararpour, L | 1 |
| Kelley, RG | 1 |
| Spielman, D | 3 |
| Chang, KD | 2 |
| Geoffroy, PA | 1 |
| Bellivier, F | 1 |
| Leboyer, M | 1 |
| Etain, B | 1 |
| Ohnishi, T | 1 |
| Murata, T | 1 |
| Watanabe, A | 1 |
| Hida, A | 1 |
| Ohba, H | 1 |
| Iwayama, Y | 1 |
| Mishima, K | 1 |
| Gondo, Y | 1 |
| Yoshikawa, T | 1 |
| Shtein, L | 1 |
| Agam, G | 11 |
| Belmaker, RH | 17 |
| Bersudsky, Y | 7 |
| Gattaz, WF | 1 |
| Zanetti, MV | 1 |
| Carvalho, AF | 1 |
| Chan, J | 1 |
| Tarko, L | 1 |
| Hernandez, M | 1 |
| Davis, J | 1 |
| Woodworth, KY | 1 |
| Solmi, M | 1 |
| Veronese, N | 1 |
| Zaninotto, L | 1 |
| van der Loos, ML | 1 |
| Gao, K | 1 |
| Schaffer, A | 1 |
| Reis, C | 1 |
| Normann, C | 1 |
| Anghelescu, IG | 1 |
| Correll, CU | 1 |
| Tan, HZ | 1 |
| Li, H | 2 |
| Liu, CF | 1 |
| Guan, JT | 1 |
| Guo, XB | 1 |
| Wen, CH | 1 |
| Ou, SM | 1 |
| Zhang, YN | 1 |
| Zhang, J | 3 |
| Xu, CT | 1 |
| Shen, ZW | 1 |
| Wu, RH | 3 |
| Wang, XQ | 1 |
| Xu, H | 1 |
| Zhang, Y | 1 |
| Guan, J | 1 |
| Xu, C | 1 |
| Shen, Z | 1 |
| Xiao, B | 1 |
| Liang, C | 1 |
| Chen, K | 1 |
| Wu, R | 1 |
| Jadhav, S | 1 |
| Russo, S | 1 |
| Cowart, LA | 1 |
| Greenberg, ML | 5 |
| Forester, BP | 1 |
| Finn, CT | 1 |
| Berlow, YA | 1 |
| Wardrop, M | 2 |
| Renshaw, PF | 3 |
| Moore, CM | 3 |
| Ding, D | 1 |
| Shi, Y | 1 |
| Shaltiel, G | 3 |
| Azab, AN | 2 |
| Pullumbi, E | 1 |
| Campbell, A | 1 |
| Mehta, DV | 2 |
| Chesebro, JE | 1 |
| Patel, NC | 2 |
| Cecil, KM | 2 |
| Strakowski, SM | 3 |
| Adler, CM | 2 |
| DelBello, MP | 2 |
| Dickstein, DP | 2 |
| Towbin, KE | 2 |
| Van Der Veen, JW | 2 |
| Rich, BA | 1 |
| Brotman, MA | 1 |
| Knopf, L | 2 |
| Onelio, L | 1 |
| Pine, DS | 2 |
| Leibenluft, E | 2 |
| Potter, M | 1 |
| Moses, A | 1 |
| Deranieh, RM | 1 |
| Teo, R | 1 |
| King, J | 1 |
| Dalton, E | 1 |
| Ryves, J | 1 |
| Williams, RS | 2 |
| Harwood, AJ | 3 |
| Terbach, N | 1 |
| Scherk, H | 3 |
| Backens, M | 3 |
| Schneider-Axmann, T | 3 |
| Usher, J | 3 |
| Kemmer, C | 3 |
| Reith, W | 3 |
| Falkai, P | 3 |
| Gruber, O | 3 |
| Parikh, SV | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Silverstone, PH | 5 |
| McGrath, BM | 3 |
| Caetano, SC | 1 |
| Olvera, RL | 1 |
| Hatch, JP | 1 |
| Sanches, M | 1 |
| Chen, HH | 1 |
| Nicoletti, M | 2 |
| Stanley, JA | 2 |
| Fonseca, M | 1 |
| Hunter, K | 1 |
| Pliszka, SR | 1 |
| Soares, JC | 2 |
| Libby, A | 1 |
| Adams, E | 1 |
| Acquaye, T | 1 |
| Kelley, R | 2 |
| Reiss, A | 1 |
| Chang, K | 1 |
| Delbello, M | 1 |
| Chu, WJ | 1 |
| Garrett, A | 1 |
| Mills, N | 1 |
| Bryan, H | 1 |
| Adler, C | 1 |
| Eliassen, J | 1 |
| Sylvia, LG | 1 |
| Peters, AT | 1 |
| Deckersbach, T | 1 |
| Nierenberg, AA | 3 |
| Singh, N | 1 |
| Halliday, AC | 1 |
| Thomas, JM | 1 |
| Kuznetsova, OV | 1 |
| Baldwin, R | 1 |
| Woon, EC | 1 |
| Aley, PK | 1 |
| Antoniadou, I | 1 |
| Sharp, T | 1 |
| Vasudevan, SR | 1 |
| Churchill, GC | 1 |
| Pies, R | 1 |
| Patocka, J | 1 |
| Klár, I | 1 |
| Strunecká, A | 1 |
| O'Donnell, T | 2 |
| Ulrich, M | 2 |
| Asghar, SJ | 2 |
| Hanstock, CC | 2 |
| Shamir, A | 1 |
| Steen, VM | 1 |
| Davanzo, P | 2 |
| Yue, K | 2 |
| Thomas, MA | 2 |
| Belin, T | 2 |
| Mintz, J | 1 |
| Venkatraman, TN | 1 |
| Santoro, E | 1 |
| Barnett, S | 1 |
| McCracken, J | 2 |
| Pilcher, HR | 1 |
| Allan, SJ | 1 |
| Kavanagh, GM | 1 |
| Herd, RM | 1 |
| Savin, JA | 1 |
| Williams, R | 1 |
| Ryves, WJ | 1 |
| Dalton, EC | 1 |
| Eickholt, B | 1 |
| Frey, BN | 1 |
| Folgierini, M | 1 |
| Kapczinski, F | 2 |
| Kim, H | 2 |
| Brandish, PE | 1 |
| Su, M | 1 |
| Holder, DJ | 1 |
| Hodor, P | 1 |
| Szumiloski, J | 1 |
| Kleinhanz, RR | 1 |
| Forbes, JE | 1 |
| McWhorter, ME | 1 |
| Duenwald, SJ | 1 |
| Parrish, ML | 1 |
| Na, S | 1 |
| Liu, Y | 1 |
| Phillips, RL | 1 |
| Renger, JJ | 1 |
| Sankaranarayanan, S | 1 |
| Simon, AJ | 1 |
| Scolnick, EM | 1 |
| Ostacher, MJ | 1 |
| Calabrese, JR | 1 |
| Ketter, TA | 1 |
| Marangell, LB | 1 |
| Miklowitz, DJ | 1 |
| Miyahara, S | 1 |
| Bauer, MS | 1 |
| Thase, ME | 1 |
| Wisniewski, SR | 1 |
| Sachs, GS | 2 |
| Mick, E | 1 |
| Aleardi, M | 1 |
| Dougherty, M | 1 |
| Harpold, T | 1 |
| Hammerness, P | 1 |
| Randall, E | 1 |
| Shaldubina, A | 2 |
| Stahl, Z | 1 |
| Furszpan, M | 1 |
| Regenold, WT | 1 |
| Shapiro, J | 4 |
| Eden Evins, A | 1 |
| Demopulos, C | 1 |
| Yovel, I | 1 |
| Culhane, M | 1 |
| Ogutha, J | 1 |
| Grandin, LD | 1 |
| Johanson, RA | 1 |
| O'Brien, WT | 1 |
| Buccafusca, R | 1 |
| Klein, PS | 1 |
| Berry, GT | 1 |
| Yildiz-Yesiloglu, A | 1 |
| Ankerst, DP | 1 |
| Bryan, HS | 1 |
| Stanford, KE | 1 |
| McQuillin, A | 1 |
| Rizig, M | 1 |
| Gurling, HM | 1 |
| Malhi, GS | 1 |
| Ivanovski, B | 1 |
| Wen, W | 1 |
| Lagopoulos, J | 1 |
| Moss, K | 1 |
| Sachdev, P | 1 |
| Kraft, S | 1 |
| Meyer, J | 1 |
| Port, JD | 1 |
| Unal, SS | 1 |
| Mrazek, DA | 1 |
| Marcus, SM | 1 |
| Lan, MJ | 1 |
| McLoughlin, GA | 1 |
| Griffin, JL | 1 |
| Tsang, TM | 1 |
| Huang, JT | 1 |
| Yuan, P | 1 |
| Manji, H | 1 |
| Holmes, E | 1 |
| Bahn, S | 1 |
| Bogarapu, S | 1 |
| Bishop, JR | 1 |
| Krueger, CD | 1 |
| Pavuluri, MN | 1 |
| Levine, J | 6 |
| Barak, Y | 3 |
| Kofman, O | 6 |
| Gonzalves, M | 1 |
| Szor, H | 1 |
| Elizur, A | 1 |
| Grisaru, N | 1 |
| Witztum, E | 1 |
| Greenberg, BD | 1 |
| Lenox, RH | 1 |
| McNamara, RK | 1 |
| Watterson, JM | 1 |
| Watson, DG | 1 |
| Kurtzman, L | 1 |
| Rapoport, A | 1 |
| Zimmerman, J | 1 |
| Shimon, H | 1 |
| Hyde, TM | 1 |
| Kleinman, JE | 1 |
| van Calker, D | 2 |
| Richards, MH | 1 |
| Moore, GJ | 1 |
| Bebchuk, JM | 1 |
| Parrish, JK | 1 |
| Faulk, MW | 1 |
| Arfken, CL | 1 |
| Strahl-Bevacqua, J | 1 |
| Manji, HK | 1 |
| Wolfson, M | 1 |
| Zinger, E | 1 |
| Simkin, M | 1 |
| Hertz, L | 1 |
| Biegon, A | 1 |
| Seker, A | 1 |
| Oshiro, T | 1 |
| Strober, M | 1 |
| Breeze, JL | 1 |
| Gruber, SA | 1 |
| Babb, SM | 1 |
| Frederick, BB | 1 |
| Villafuerte, RA | 1 |
| Stoll, AL | 1 |
| Hennen, J | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Salinas, PC | 1 |
| Hall, AC | 1 |
| Chengappa, KN | 1 |
| Gershon, S | 1 |
| Mallinger, AG | 1 |
| Hardan, A | 1 |
| Vagnucci, A | 1 |
| Pollock, B | 1 |
| Luther, J | 1 |
| Buttenfield, J | 1 |
| Verfaille, S | 1 |
| Kupfer, DJ | 1 |
| Viale, CI | 1 |
| Vainer, E | 1 |
| Nemanov, L | 1 |
| Ebstein, RP | 1 |
| Barkai, AI | 1 |
| Dunner, DL | 1 |
| Gross, HA | 1 |
| Mayo, P | 1 |
| Fieve, RR | 1 |
| Sharma, R | 1 |
| Venkatasubramanian, PN | 1 |
| Bárány, M | 1 |
| Davis, JM | 1 |
| Souza, FG | 1 |
| Mander, AJ | 1 |
| Foggo, M | 1 |
| Dick, H | 1 |
| Shearing, CH | 1 |
| Goodwin, GM | 1 |
| Banks, RE | 1 |
| Aiton, JF | 1 |
| Cramb, G | 1 |
| Naylor, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Inositol and Omega-3 Fatty Acids in Pediatric Mania[NCT01396486] | Phase 4 | 69 participants (Actual) | Interventional | 2012-02-03 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder[NCT02811133] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-08-31 | Withdrawn (stopped due to Funding terminated) | ||
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558] | 5,000 participants | Interventional | 1998-09-30 | Completed | |||
| Investigation of the Effects of in Vivo Lithium Treatment on Gene Expression Levels Using Lymphoblastoid Cell Lines From Human Healthy Subjects[NCT01565759] | Phase 1 | 20 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients.[NCT01246310] | 24 participants (Actual) | Interventional | 2010-11-30 | Terminated (stopped due to The number of patients enrolled was insufficient to match the calculated sample size and to carry out statistical analyses) | |||
| Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients[NCT00870311] | Phase 4 | 28 participants (Actual) | Interventional | 1996-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT01396486)
Timeframe: Baseline to endpoint (12 weeks or last observation carried forward if dropped prior to week 12)
| Intervention | units on a scale (Mean) |
|---|---|
| Omega-3/Placebo | -4.9 |
| Placebo/Inositol | -5.6 |
| Omega-3/Inositol | -10.8 |
The Young Mania Rating Scale (YMRS) consists of 7 items rated on a scale from 0 (symptoms not present) to 4 (symptoms extremely severe) and 4 items rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe).The YMRS score ranges from 0-60. Questions are asked about the last week. A higher score signifies more severe manic symptoms. (NCT01396486)
Timeframe: Baseline to endpoint (12 weeks or last observation carried forward if dropped prior to week 12)
| Intervention | units on a scale (Mean) |
|---|---|
| Omega-3/Placebo | -4.8 |
| Placebo/Inositol | -6.4 |
| Omega-3/Inositol | -10.2 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
24 reviews available for inositol and Bipolar Disorder
| Article | Year |
|---|---|
Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid.
Topics: Antimanic Agents; Bipolar Disorder; Dietary Supplements; Humans; Inositol; Lithium Compounds; Medica | 2021 |
Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase.
Topics: Animals; Biological Products; Bipolar Disorder; Disease Models, Animal; Fatty Acids, Omega-3; Gallic | 2021 |
Proton magnetic resonance spectroscopy changes after lithium treatment. Systematic review.
Topics: Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Choline; Cross-Sectional Studies; gamma-Am | 2018 |
Can the response to mood stabilizers be predicted in bipolar disorder?
Topics: Antimanic Agents; Bipolar Disorder; Circadian Rhythm Signaling Peptides and Proteins; Genetic Associ | 2014 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2016 |
Alternative treatments in pediatric bipolar disorder.
Topics: Acupuncture; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Humans; Hypericum; Inos | 2009 |
Cellular consequences of inositol depletion.
Topics: Bipolar Disorder; Diglycerides; Glycogen Synthase Kinase 3; Humans; Inositol; Inositol Phosphates; L | 2009 |
Structure-function studies for the panacea, valproic acid.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Epilepsy; gamma-Aminobutyric Acid; Glycogen Synthase Kin | 2009 |
Lithium and valproate and their possible effects on themyo-inositol second messenger system in healthy volunteers and bipolar patients.
Topics: Affect; Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Humans; Inositol; Lithi | 2009 |
Nutrient-based therapies for bipolar disorder: a systematic review.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Choline; Chromium; Dietary Supplements; | 2013 |
[Molecular mechanisms of biological effects of lithium].
Topics: Animals; Bipolar Disorder; Brain; Enzyme Inhibitors; Glycogen; Humans; Inositol; Lithium | 2002 |
Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Blood Cells; Enzyme Inhibitors; Eukaryotic Cells; H | 2002 |
A molecular cell biology of lithium.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Cytoskeleton; Glycogen Synthase Kinase 3; Growth Cones; | 2004 |
Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Humans; Inositol; Lithium Compounds; Signal Tran | 2005 |
Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia; Bipolar Disorder; Frontal Lobe; | 2005 |
A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies.
Topics: Bipolar Disorder; Feeding and Eating Disorders; Humans; Inositol; Magnetic Resonance Spectroscopy; M | 2005 |
Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain Chemistry; Child; Choline; Creatine; Glutamic Acid; Gl | 2006 |
Lithium-pilocarpine seizures as a model for lithium action in mania.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Humans; Inositol; Limbic System | 2007 |
Complementary medicines in pediatric bipolar disorder.
Topics: Adolescent; Bipolar Disorder; Child; Choline; Complementary Therapies; Drug Therapy, Combination; Fa | 2008 |
Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
Topics: Adult; Aged; Animals; Behavior, Animal; Bipolar Disorder; Brain; Clinical Trials as Topic; Depressiv | 1993 |
How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Blood-Brain Barrier; Brain; Depressive Disorder; Diures | 1996 |
Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on the PI cycle: depletion by chronic lithium of brain inositol is specific to hypothalamus, and inositol levels may be abnormal in postmortem br
Topics: Aged; Animals; Antimanic Agents; Behavior; Behavior, Animal; Bipolar Disorder; Brain Chemistry; Fema | 1998 |
The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder.
Topics: Antimanic Agents; Biological Transport, Active; Bipolar Disorder; Carbamazepine; Carrier Proteins; D | 2000 |
Lithium and synaptic plasticity.
Topics: Antimanic Agents; Bipolar Disorder; Brain Chemistry; Calcium-Calmodulin-Dependent Protein Kinases; G | 1999 |
18 trials available for inositol and Bipolar Disorder
| Article | Year |
|---|---|
A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5-12.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; | 2022 |
A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study.
Topics: Bipolar Disorder; Child; Child, Preschool; Docosahexaenoic Acids; Double-Blind Method; Drug Therapy, | 2015 |
Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Cross-Sectional S | 2008 |
Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.
Topics: Adolescent; Antimanic Agents; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar | 2009 |
Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression.
Topics: Adolescent; Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Child; Dibenzothiazepines; Female | 2012 |
Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients.
Topics: Adult; Algorithms; Antimanic Agents; Bipolar Disorder; Brain Chemistry; Female; Frontal Lobe; Humans | 2002 |
Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Cerebral Cortex; Ch | 2003 |
The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cross-Over Studies; Dietary Supplements; Double-Blind Met | 2004 |
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Di | 2006 |
Inositol deficiency diet and lithium effects.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Diet; Female; Frontal Lobe; Humans; Inositol | 2006 |
Inositol augmentation of lithium or valproate for bipolar depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale | 2006 |
Lithium treatment effects on Myo-inositol in adolescents with bipolar depression.
Topics: Adolescent; Antidepressive Agents; Aspartic Acid; Bipolar Disorder; Child; Female; Humans; Inositol; | 2006 |
Proton magnetic resonance spectroscopy in youth with severe mood dysregulation.
Topics: Antimanic Agents; Arousal; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar Dis | 2008 |
Follow-up and relapse analysis of an inositol study of depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Fo | 1995 |
Double-blind, controlled trial of inositol treatment of depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; M | 1995 |
Double-blind, controlled trial of inositol treatment of depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; M | 1995 |
Double-blind, controlled trial of inositol treatment of depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; M | 1995 |
Double-blind, controlled trial of inositol treatment of depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; M | 1995 |
Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder.
Topics: Adolescent; Area Under Curve; Aspartic Acid; Bipolar Disorder; Child; Creatine; Demography; Drug Adm | 2001 |
Inositol as an add-on treatment for bipolar depression.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Blood-Brain Barrier; Carbamazepine; Drug | 2000 |
The effects of lithium discontinuation and the non-effect of oral inositol upon thyroid hormones and cortisol in patients with bipolar affective disorder.
Topics: Adult; Aged; Bipolar Disorder; Double-Blind Method; Female; Humans; Hydrocortisone; Inositol; Lithiu | 1991 |
52 other studies available for inositol and Bipolar Disorder
| Article | Year |
|---|---|
Stereochemistry at phosphorus of the reaction catalyzed by myo-inositol monophosphatase.
Topics: Bipolar Disorder; Catalysis; Lithium; Nuclear Magnetic Resonance, Biomolecular; Phosphates; Phosphor | 2002 |
Neurochemical correlates of cognitive functions in euthymic patients with bipolar disorder:
Topics: Bipolar Disorder; Cognition; Glutamates; Glutamine; Humans; Inositol; Magnetic Resonance Spectroscop | 2022 |
Anterior cingulate cortex neuro-metabolic changes underlying lithium-induced euthymia in bipolar depression: A longitudinal
Topics: Aspartic Acid; Bipolar Disorder; Brain; Choline; Creatine; Gyrus Cinguli; Humans; Inositol; Lithium; | 2021 |
Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Body Mass Index; Brain; Case-Control Studies; Cr | 2017 |
Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A
Topics: Adult; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Brain Chemistry; Choline; Cyclothym | 2018 |
Lithium and fluoxetine regulate the rate of phosphoinositide synthesis in neurons: a new view of their mechanisms of action in bipolar disorder.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Cerebral Cort | 2018 |
(1)H-MRS of hippocampus in patients after first manic episode.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Glutamic Acid; Glutamine; Hip | 2014 |
Prospective neurochemical characterization of child offspring of parents with bipolar disorder.
Topics: Adolescent; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Child; Child of Impaired Parents; | 2013 |
Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis.
Topics: Amino Acid Sequence; Animals; Behavior, Animal; Bipolar Disorder; Brain; Brain Diseases; Circadian R | 2014 |
Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder.
Topics: Animals; Antimanic Agents; Behavior; Behavior, Animal; Bipolar Disorder; Diet; Enzyme Inhibitors; In | 2015 |
A Longitudinal (6-week) 3T (1)H-MRS Study on the Effects of Lithium Treatment on Anterior Cingulate Cortex Metabolites in Bipolar Depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Female; Glutamic Acid; Glutamine; Gyrus Cinguli; Hum | 2015 |
Main Effects of Diagnoses, Brain Regions, and their Interaction Effects for Cerebral Metabolites in Bipolar and Unipolar Depressive Disorders.
Topics: Adult; Aspartic Acid; Biomarkers; Bipolar Disorder; Case-Control Studies; Choline; Creatine; Depress | 2016 |
Differential neurometabolite alterations in brains of medication-free individuals with bipolar disorder and those with unipolar depression: a two-dimensional proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Depressive Disorder; Female; Gyrus Cingul | 2016 |
Inositol Depletion Induced by Acute Treatment of the Bipolar Disorder Drug Valproate Increases Levels of Phytosphingosine.
Topics: Acetyltransferases; Antimanic Agents; Bipolar Disorder; Ceramides; Down-Regulation; Humans; Inositol | 2017 |
Yeast bioassay for identification of inositol depleting compounds.
Topics: Anticonvulsants; Antimanic Agents; Biological Assay; Bipolar Disorder; Brain; Carboxylic Acids; Cell | 2009 |
Ethylbutyrate, a valproate-like compound, exhibits inositol-depleting effects--a potential mood-stabilizing drug.
Topics: Affect; Bipolar Disorder; Butyrates; Cell Proliferation; Humans; Inositol; Intramolecular Lyases; Sa | 2009 |
Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aspartic Acid; Bipolar Dis | 2008 |
PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Chemotaxis; Humans; Inositol; Lithium Co | 2009 |
Cortical neurochemistry in euthymic patients with bipolar I disorder.
Topics: Adult; Affect; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dominance, Cere | 2009 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Brain Chemistry; Child; Diagnostic and Statistical Manu | 2011 |
Neurochemical deficits in the cerebellar vermis in child offspring of parents with bipolar disorder.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Brain Chemistry; Cerebellum; Child; Choline; Female; Hu | 2011 |
A safe lithium mimetic for bipolar disorder.
Topics: Animals; Azoles; Behavior, Animal; Bipolar Disorder; Blood-Brain Barrier; Enzyme Inhibitors; Humans; | 2013 |
The role of micronutrients as possible mood-stabilizing agents.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Child; Chromium; Cognition Disorders; Dietary Supple | 2002 |
Does inositol signalling have a role in disease susceptibility and drug treatment of bipolar disorder?
Topics: Bipolar Disorder; Disease Susceptibility; Humans; Inositol; Lithium; Phosphoric Monoester Hydrolases | 2002 |
Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents.
Topics: Adolescent; Age Factors; Aspartic Acid; Bipolar Disorder; Child; Choline; Creatine; Diagnosis, Diffe | 2003 |
Drug research: the ups and downs of lithium.
Topics: Affect; Alzheimer Disease; Animals; Bipolar Disorder; Brain; Glycogen Synthase Kinase 3; Humans; Ino | 2003 |
A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Choli | 2005 |
Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex.
Topics: Animals; Antimanic Agents; Biomarkers; Biopterins; Bipolar Disorder; Cerebral Cortex; Cytidine Dipho | 2005 |
Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brain Chem | 2006 |
SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Brain; Genotype; Glycogen Synthase Kinase 3; Glycogen S | 2006 |
A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder.
Topics: Affect; Animals; Bipolar Disorder; Brain; Gene Expression Profiling; Inositol; Lithium; Lithium Carb | 2007 |
Measuring mania metabolites: a longitudinal proton spectroscopy study of hypomania.
Topics: Adult; Affect; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Brain Mapping; Choline; Energy Metabo | 2007 |
Dopamine transporter genotype influences N-acetyl-aspartate in the left putamen.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dominance, Cerebral; Dopamine Plasma Memb | 2009 |
Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic resonance spectroscopic imaging study.
Topics: Adolescent; Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Brain; Case-Control Studies; Caud | 2008 |
Neurochemical pathology in hippocampus in euthymic patients with bipolar I disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Dysthymic Disorder; Female; Hippocampus; | 2008 |
Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.
Topics: Adult; Analysis of Variance; Animals; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Case-Contro | 2009 |
Lithium dosage and inositol levels.
Topics: Bipolar Disorder; Dose-Response Relationship, Drug; Humans; Inositol; Lithium; Male; Middle Aged; Ps | 1994 |
Inositol-induced mania?
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Inositol; Ma | 1996 |
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
Topics: Animals; Bipolar Disorder; Blotting, Western; Carbamazepine; Cell Line; Dose-Response Relationship, | 1996 |
CSF inositol does not predict antidepressant response to inositol. Short communication.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Case-Control Studies; Depressive Disorder; Fem | 1996 |
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Brain; Brain Chemistry; Cerebellum; Female; Frontal Lobe; Humans; Ino | 1997 |
Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness.
Topics: Adult; Analysis of Variance; Bipolar Disorder; Depression, Chemical; Female; Frontal Lobe; Humans; I | 1999 |
Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations.
Topics: Antimanic Agents; Astrocytoma; Bipolar Disorder; Brain; Brain Neoplasms; Carbamazepine; Dose-Respons | 2000 |
Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Bipolar Disorder; Brain; Depressive Disorder | 2000 |
Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex.
Topics: Adult; Affect; Bipolar Disorder; Brain Mapping; Choline; Dominance, Cerebral; Female; Gyrus Cinguli; | 2000 |
Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol.
Topics: Adult; Bipolar Disorder; Caffeine; Humans; Inositol; Male; Taurine | 2001 |
Reduced inositol content in lymphocyte-derived cell lines from bipolar patients.
Topics: Bipolar Disorder; Brain; Cells, Cultured; Chromatography, Gas; Female; Frontal Lobe; Humans; Inosito | 2002 |
Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder.
Topics: Bipolar Disorder; Depression; Fructose; Glucose; Humans; Inositol; Probenecid | 1978 |
Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients.
Topics: Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Choline; Creatine; Depressive Disorder; Energ | 1992 |
Incorporation of inositol into the phosphoinositides of lymphoblastoid cell lines established from bipolar manic-depressive patients.
Topics: Bipolar Disorder; Cell Line; Female; Humans; Inositol; Lymphocytes; Male; Middle Aged; Phosphatidyli | 1990 |
Lithium research: state of the art.
Topics: Animals; Bipolar Disorder; Brain; Depressive Disorder; Humans; Inositol; Inositol Phosphates; Lithiu | 1990 |